Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Ketaiya Biotechnology

Request full access

Developing and commercializing bio-based technologies and products

ChinaFounded 2021Energy

About Shanghai Ketaiya Biotechnology

Shanghai Ketaiya Biotechnology Co., Ltd. (Cataya Bio), established in September 2021, is a synthetic biology company focused on the biomanufacturing of high-value chemical and biochemical products. The company was founded by Dr. Lishan Zhao, who serves as CEO, along with a team of experienced professionals from the synthetic biology industry. Dr. Zhao brings over two decades of experience, having previously served as the Vice President of Research and Development at Amyris from 2008 to 2021, where he was instrumental in developing a world-class synthetic biology platform and commercializing over ten products. The founding team's collective experience, totaling more than 40 years, includes veterans from companies like Meihua Group and Evonik, covering areas from strain engineering to commercialization.

Cataya Bio operates by engineering microbes and developing clean fermentation processes to produce high-purity products. The company is building an end-to-end business, from technology development to manufacturing and sales. Its business model revolves around providing natural, green, and sustainable raw materials for a variety of markets, including personal care, food and nutrition, and pharmaceutical ingredients. By leveraging synthetic biology, Cataya aims to offer an alternative to petroleum-based production methods. The company's product pipeline includes high-value molecules such as terpenoids, amino acids and their derivatives, and oligosaccharides. With a research and development center in Shanghai's Zhangjiang Hi-Tech Park and operations in Japan and the US, the company is positioned for global reach.

The core of the company's operations is its advanced engineering biology platform, which integrates data science, automation, and high-throughput technologies to accelerate research and development. This platform, referred to as "DBTL" (Design-Build-Test-Learn), covers the entire workflow from strain and enzyme engineering to fermentation, purification, and scaled-up production. In May 2022, the company received a grant from the Shanghai Municipal Commission of Science and Technology to further integrate AI into its platform for intelligent microbial cell factory design. Cataya has successfully attracted significant investment, completing four funding rounds within two years of its inception, including a Series B round of CNY 250 million in September 2023, bringing its total funding to nearly CNY 500 million. Key investors include Eight Roads, Sequoia China, Source Code Capital, and Bits x Bites.

Source: Dealroom company data

At a glance

Status
Operational
Employees
8
Open positions
None listed
Dealroom signal
85.8/100
Industry
Energy
Sector
Biotechnology, Hard Tech
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2023 $34M $138M Eight Roads Ventures · Henan Investment Group · Shixin Capital · Hengxu Capital ↗
SERIES A✓Equity / VC May 2022 $14M $55M Sherpa Investment · Food Core Capital · Source Code Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Ketaiya Biotechnology website traffic

Latest recorded traffic for Shanghai Ketaiya Biotechnology is 480 monthly website visits, up 108.7% over the last three months. Shanghai Ketaiya Biotechnology's team grew 60% over the past year.

Latest monthly visits480 3-month web change+108.7% 1-year team growth+60%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Ketaiya Biotechnology in its local ecosystem

Live from Dealroom

The Shanghai Ketaiya Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States66.7%
🇨🇳 China33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Ketaiya Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Ketaiya Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.